Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+ - NCT05139017RecruitingPhase 2/Phase 3
Test drug Zilovertamab vedotin with standard care for lymphoma
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
Glendale, ArizonaAges 18 years+ - NCT05139056RecruitingPhase 1
Stem cell virus therapy for recurrent brain tumors
This trial tests a new treatment that uses specially modified stem cells (taken from donors) to deliver a virus directly into the tumor during surgery. The goal is to see if it is safe and effective for brain tumors that have come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT05183490RecruitingPhase 1
Cell therapy for repeated viral infections after transplant
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
New York, New YorkAges 18 years+ - NCT05141058RecruitingPhase 1
T cell therapy to help prevent COVID-19 after transplant
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
Washington D.C., District of ColumbiaAges 2–80 - NCT05182957RecruitingPhase 2
Study of anti-PD-1, lenalidomide, and azacitidine for PTCL
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
Suzhou, JiangsuAges 18 years+ - NCT05183048RecruitingEarly Phase 1
Test a new PET scan to find head and neck cancer
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
Birmingham, AlabamaAges 18 years+ - NCT05112601RecruitingPhase 2
Nivolumab plus or minus ipilimumab for dMMR endometrial cancer
This Phase 2 study tests the medicines nivolumab (with or without ipilimumab) in people with recurrent endometrial cancer that has “dMMR” (a specific tumor DNA repair defect). It aims to see whether this immune-based treatment can shrink tumors or help them stop growing.
Birmingham, AlabamaAges 18 years+ - NCT05100069Recruiting
Survey about brigatinib for ALK-positive lung cancer
This trial is a survey study about how brigatinib is used for people with certain advanced lung cancer. It may help doctors understand real-world treatment patterns and experiences for ALK-positive non-small cell lung cancer.
TokyoAges Any age - NCT05135091RecruitingPhase 3
Cell therapy trial for hard-to-control one-sided temporal lobe epilepsy
This Phase 3 study tests a neural cell therapy (NRTX-1001) for adults whose seizures come from one side of the hippocampus and have not improved with standard seizure medicines. The goal is to reduce seizure frequency and improve seizure control where other treatments have not worked.
Birmingham, AlabamaAges 18–75 - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Gilbert, ArizonaAges 18 years+ - NCT05127824RecruitingPhase 2
Kidney cancer vaccine made from your own immune cells
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05100095RecruitingPhase 2
Radiation schedule study for Merkel cell skin cancer
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Houston, TexasAges 18 years+ - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT05054361Recruiting
Study gut immunity changes in children with type 1 diabetes
This study looks at how a type of immune cell (MAIT cells) and the gut (microbiota and gut lining) change around the time type 1 diabetes starts in children. It may help researchers understand why type 1 diabetes begins and how the gut and immune system are connected.
AntonyAges 1–15 - NCT05061550RecruitingPhase 2
Targeted immune-plus-chemo treatment before and after lung surgery
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Little Rock, ArkansasAges 18–95 - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT05041309Enrolling by invitation
Long-term follow-up after gene-modified cell treatment
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
Gilbert, ArizonaAges Any age - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT05023265Recruiting
Study quality of life after SBRT for kidney cancer
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
Toronto, OntarioAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.